Developing large language models to detect adverse drug events in posts on x.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Yu Deng, Yunzhao Xing, Jason Quach, Xiaotian Chen, Xiaoqiang Wu, Yafei Zhang, Charlotte Moureaud, Mengjia Yu, Yujie Zhao, Li Wang, Sheng Zhong
{"title":"Developing large language models to detect adverse drug events in posts on x.","authors":"Yu Deng, Yunzhao Xing, Jason Quach, Xiaotian Chen, Xiaoqiang Wu, Yafei Zhang, Charlotte Moureaud, Mengjia Yu, Yujie Zhao, Li Wang, Sheng Zhong","doi":"10.1080/10543406.2024.2403442","DOIUrl":null,"url":null,"abstract":"<p><p>Adverse drug events (ADEs) are one of the major causes of hospital admissions and are associated with increased morbidity and mortality. Post-marketing ADE identification is one of the most important phases of drug safety surveillance. Traditionally, data sources for post-marketing surveillance mainly come from spontaneous reporting system such as the Food and Drug Administration Adverse Event Reporting System (FAERS). Social media data such as posts on X (formerly Twitter) contain rich patient and medication information and could potentially accelerate drug surveillance research. However, ADE information in social media data is usually locked in the text, making it difficult to be employed by traditional statistical approaches. In recent years, large language models (LLMs) have shown promise in many natural language processing tasks. In this study, we developed several LLMs to perform ADE classification on X data. We fine-tuned various LLMs including BERT-base, Bio_ClinicalBERT, RoBERTa, and RoBERTa-large. We also experimented ChatGPT few-shot prompting and ChatGPT fine-tuned on the whole training data. We then evaluated the model performance based on sensitivity, specificity, negative predictive value, positive predictive value, accuracy, F1-measure, and area under the ROC curve. Our results showed that RoBERTa-large achieved the best F1-measure (0.8) among all models followed by ChatGPT fine-tuned model with F1-measure of 0.75. Our feature importance analysis based on 1200 random samples and RoBERTa-Large showed the most important features are as follows: \"withdrawals\"/\"withdrawal\", \"dry\", \"dealing\", \"mouth\", and \"paralysis\". The good model performance and clinically relevant features show the potential of LLMs in augmenting ADE detection for post-marketing drug safety surveillance.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-12"},"PeriodicalIF":1.2000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2024.2403442","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Adverse drug events (ADEs) are one of the major causes of hospital admissions and are associated with increased morbidity and mortality. Post-marketing ADE identification is one of the most important phases of drug safety surveillance. Traditionally, data sources for post-marketing surveillance mainly come from spontaneous reporting system such as the Food and Drug Administration Adverse Event Reporting System (FAERS). Social media data such as posts on X (formerly Twitter) contain rich patient and medication information and could potentially accelerate drug surveillance research. However, ADE information in social media data is usually locked in the text, making it difficult to be employed by traditional statistical approaches. In recent years, large language models (LLMs) have shown promise in many natural language processing tasks. In this study, we developed several LLMs to perform ADE classification on X data. We fine-tuned various LLMs including BERT-base, Bio_ClinicalBERT, RoBERTa, and RoBERTa-large. We also experimented ChatGPT few-shot prompting and ChatGPT fine-tuned on the whole training data. We then evaluated the model performance based on sensitivity, specificity, negative predictive value, positive predictive value, accuracy, F1-measure, and area under the ROC curve. Our results showed that RoBERTa-large achieved the best F1-measure (0.8) among all models followed by ChatGPT fine-tuned model with F1-measure of 0.75. Our feature importance analysis based on 1200 random samples and RoBERTa-Large showed the most important features are as follows: "withdrawals"/"withdrawal", "dry", "dealing", "mouth", and "paralysis". The good model performance and clinically relevant features show the potential of LLMs in augmenting ADE detection for post-marketing drug safety surveillance.

开发大型语言模型,检测 x 上帖子中的药物不良事件。
药物不良事件 (ADE) 是导致入院治疗的主要原因之一,并与发病率和死亡率的增加有关。上市后 ADE 识别是药物安全性监测最重要的阶段之一。传统上,上市后监测的数据源主要来自自发报告系统,如食品药品管理局不良事件报告系统(FAERS)。X (原 Twitter)上的帖子等社交媒体数据包含丰富的患者和用药信息,有可能加速药物监测研究。然而,社交媒体数据中的 ADE 信息通常被锁定在文本中,很难被传统的统计方法所利用。近年来,大型语言模型(LLM)在许多自然语言处理任务中都显示出了良好的前景。在本研究中,我们开发了几种 LLM,用于对 X 数据进行 ADE 分类。我们对各种 LLM 进行了微调,包括 BERT-base、Bio_ClinicalBERT、RoBERTa 和 RoBERTa-large。我们还实验了 ChatGPT 少量提示和 ChatGPT 在整个训练数据上的微调。然后,我们根据灵敏度、特异性、阴性预测值、阳性预测值、准确度、F1-measure 和 ROC 曲线下面积对模型性能进行了评估。结果显示,在所有模型中,RoBERTa-large 的 F1 值(0.8)最好,其次是 ChatGPT 微调模型,F1 值为 0.75。基于 1200 个随机样本和 RoBERTa-Large 的特征重要性分析表明,最重要的特征如下:"撤回"/"戒断"、"干燥"、"交易"、"口腔 "和 "麻痹"。良好的模型性能和临床相关特征显示了 LLMs 在增强上市后药物安全监测的 ADE 检测方面的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信